Is the use of COX-2 inhibitors in gastroenterology cost-effective?

Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):60-1. doi: 10.1038/ncpgasthep0043.
No abstract available

MeSH terms

  • Cost-Benefit Analysis
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / economics*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Peptic Ulcer / chemically induced*

Substances

  • Cyclooxygenase Inhibitors